fep blue glp-1 coverage 2025 Weight Loss Drug from FEHB Plans and Medicare GLP-1 Pipeline Update: November 2025

Transdermal delivery systems could potentially offer advantages over subcutaneous injections, including improved patient acceptability and reduced injection-site reactions

The demographic distribution of those most likely to stop treatment was as follows: patients of color, men, people enrolled in Medicare or Medicaid, those living in areas with very high social needs, heart failure, obesity or other cardiovascular diseases prior to drug initiation, and those experiencing new gastrointestinal adverse effects at follow-up [132]

So overall, we would think, but don't know yet because we don't have the results, that this is a group of patients that would have a fairly low event rate for major adverse cardiovascular events, which is what's being looked at in Select and as a secondary endpoint, these kidney outcomes

S.HueyE